Opioids

April 17, 2026 | Fact Sheets, Novel Psychoactive Substances, Opioids, Substance Misuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association is monitoring the emergence of novel psychoactive substances appearing on the illicit drug market in the United States. The term “novel” does not denote a new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact examines orphines, a class of potent synthetic opioids. Orphines are a class of synthetic opioids first developed by Janssen Pharmaceuticals in the 1960s, discovered to have anesthetic properties. Drug policy experts believe that orphines are originating from clandestine laboratories in China and that their sudden rise in the illicit drug market is an attempt by clandestine chemists and international drug trafficking organizations to avoid international legal and regulatory barriers. The high potency of orphines demonstrates the need for enhanced surveillance, increased testing capabilities, and timely public health alerts. ...

February 5, 2026 | Controlled Substances, Kratom, Legal & Legislative Research, Opioids, Substance Misuse

Kratom is an herb derived from a leafy Southeast Asian tree and contains two psychoactive compounds that can bind to opioid receptors in the brain and produce a pharmacological response similar to effects produced by other opioid agonists, such as morphine. As of January 2026, 30 states and the District of Columbia regulate kratom. This document: (1) provides a singular resource for each jurisdiction’s laws; (2) allows for a comparison of these laws between jurisdictions; and (3) identifies and highlights interesting provisions....

January 23, 2026 | Controlled Substances, Innovative Initiatives, Medication Assisted Treatment (MAT), Opioids, Peer Support and Recoery Services, Prescription Drugs, Recovery, Reentry, Substance Misuse, Substance Use Disorder

Ryther, a nonprofit mental health service provider for children, teens, and young adults in Seattle, Washington, provides therapeutic services to youth struggling with mental and behavioral health issues, including substance use disorder (SUD). As part of its menu of services for SUD treatment, Ryther offers medication for addiction treatment (MAT) for those aged 12 to 25 who have opioid use disorder (OUD), making the program unique in focusing on young people. Ryther’s MAT program provides holistic treatment that addresses the physical, mental, emotional, and social challenges faced by children and young adults with SUD. Many of the participants in Ryther’s MAT program are homeless or experiencing housing instability, and the program is designed to provide these individuals with low barrier resources and support....

November 19, 2025 | Controlled Substances, Drug Courts, Harm Reduction, Law Enforcement, Legal & Legislative Research, Opioids, Prescription Drugs, Public Health, Public Safety, Substance Misuse

Psilocybin is a chemical compound produced by more than 100 species of mushrooms found growing around the world. Because of the psychedelic effects that these mushrooms produce when consumed, psilocybin-containing mushrooms have been colloquially referred to as “magic mushrooms” or “shrooms.” In this document, the Legislative Analysis and Public Policy Association (LAPPA) identifies both currently-in-force statutes/regulations and recently proposed legislation related to psilocybin throughout all 50 states, the District of Columbia, and the U.S. territories....

October 23, 2025 | Opioids, Pharmacy, Reports & Studies, Substance Use Disorder, Treatments

In collaboration with the University of Rhode Island College of Pharmacy, the Legislative Analysis and Public Policy Association (LAPPA) recently released "Pharmacists and Buprenorphine: Analysis of State Laws and Regulations." Funded by the Foundation for Opioid Response Efforts (FORE) Foundation, this project, named Pharmacy Bridge, focused on a demonstration of the real-world application and outcomes of two innovative models of pharmacy-based, low-barrier buprenorphine induction and maintenance services: (1) collaborative care through a collaborative practice agreement (CPA); and (2) independent pharmacist prescribing of buprenorphine. The report contains state-by-state descriptions and analyses of relevant statutes and regulations as well as a detailed summary of overall findings....

September 17, 2025 | Controlled Substances, Fentanyl, Harm Reduction, Law Enforcement, Legal & Legislative Research, Opioids, Public Health, Public Safety, Sharps/Syringes, Substance Misuse, Synthetic Drugs

Given the increased emphasis in recent years on using harm reduction strategies to slow the overdose crisis, the hurdle posed by state drug paraphernalia laws to freely allowing drug checking services or establishing syringe services programs is not inconspicuous. Accordingly, in 2022, LAPPA first undertook an extensive research project to determine how drug paraphernalia laws throughout the 50 states, District of Columbia, and all U.S. territories treat drug checking equipment (including fentanyl test strips and other items) and needles/syringes. This January 2024 version, which sets forth a summary of state and territory laws as of December 2023, is an update to the original report. ...

August 28, 2025 | Controlled Substances, Criminal Justice, Fact Sheets, Harm Reduction, Medication Assisted Treatment (MAT), Opioids, Recovery, Substance Misuse, Treatments

Through the use of medications for addiction treatment (MAT), an individual’s substance use, withdrawal symptoms, and the physiological and psychological cravings can be controlled, enabling the person to begin treatment while in a correctional facility and be released as a person in, or on his or her way to, recovery. Research shows that that the use of MAT for Opioid Use Disorder in correctional settings is a cost-effective and life-saving intervention....

August 11, 2025 | Controlled Substances, Harm Reduction, Legal & Legislative Research, Opioids, Pharmacy, Prescription Drugs, Public Health, Public Safety, Substance Misuse

In this document, the Legislative Analysis and Public Policy Association examines state-level legislative and administrative responses to the public health risk posed by expired and unused prescription medications. In the last several years, states, in coordination with the Federal Drug Enforcement Administration (DEA) have enacted legislation or promulgated administrative regulations to authorize drug take-back programs where expired or unused pharmaceuticals can be collected from the public by authorized persons and disposed of in a safe manner. Findings are presented by state for ease of comparison....